KIORA PHARMACEUTICALS, INC. Contract Liability (Deferred Revenue)
KIORA PHARMACEUTICALS, INC. (KPRX) had Contract Liability (Deferred Revenue) of $0 as of 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2020-03-04
- 2019-09-30: Contract with Customer, Liability, Current $0.00.
- 2018-12-31: Contract with Customer, Liability, Current $2.69M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2018-12-31 | $2.69M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |